What does LL-37 do?

LL-37 belongs to a family of peptides called cathelicidins — your innate immune system's first line of defence. When your body detects an invader, immune cells (neutrophils, macrophages) and even your skin cells release LL-37 to kill it.

What makes LL-37 special is how it kills pathogens: it physically punches holes in their cell membranes. This mechanism makes it extremely difficult for bacteria to develop resistance — unlike conventional antibiotics that target specific proteins bacteria can mutate around.

Beyond killing microbes, LL-37 also acts as an immune modulator. It recruits other immune cells to the site of infection, promotes wound healing, and — importantly — helps prevent your immune response from going overboard and causing tissue damage.

Who uses it?

• Chronic infection support — people with recurring bacterial or fungal infections
• Post-antibiotic recovery — those looking for alternatives or adjuncts to conventional antibiotics
• Immune function support — biohackers aiming to enhance innate immunity
• Wound healing — LL-37 promotes tissue repair alongside its antimicrobial action

What to know before trying

• Your body already makes it — vitamin D is a major regulator of LL-37 production. Optimising vitamin D levels (60–80 ng/mL) is the evidence-based way to increase your own LL-37
• Dose matters a lot — too much LL-37 can be pro-inflammatory and potentially harmful to your own cells
• Quality is critical — synthetic LL-37 must be high purity; contaminants could be dangerous when injected
• Short cycles typical — most users report 2–4 week protocols for acute situations, not continuous use

Frequently Asked Questions

How it works in your body

LL-37 is the only cathelicidin peptide in humans. It's stored in an inactive form (hCAP18) inside neutrophils and gets cleaved into its active 37-amino-acid form when needed. The mechanism is multi-pronged:

• Membrane disruption — LL-37 is positively charged and attracted to the negatively charged membranes of bacteria. It inserts into the membrane and forms pores, killing the microbe
• Biofilm disruption — can penetrate and break up bacterial biofilms, which are notoriously resistant to antibiotics
• Chemotaxis — recruits neutrophils, monocytes, and T-cells to the infection site
• Anti-endotoxin — neutralises LPS (bacterial endotoxin), reducing the inflammatory cascade that causes sepsis-like symptoms
• Wound healing — promotes angiogenesis and epithelial cell migration for tissue repair

Vitamin D connection

One of the most practical takeaways about LL-37: vitamin D directly controls its production. When vitamin D binds to its receptor in immune cells, it activates the gene that produces cathelicidin (the precursor to LL-37). This is one reason why vitamin D deficiency is linked to increased susceptibility to infections — your body literally makes less of its own antibiotic.

Side effects & safety

The side effect profile for supplemental LL-37 is largely unknown because no human trials exist. Based on its biology and anecdotal reports:

• Injection site reactions — pain, redness, swelling at the injection site
• Pro-inflammatory risk — at high concentrations, LL-37 can damage your own cells and trigger excessive inflammation
• Autoimmune concerns — elevated LL-37 is associated with psoriasis and rosacea; supplementation could theoretically worsen these conditions
• Unknown systemic effects — no data on what happens with repeated injections over time

Who should avoid it: People with psoriasis, rosacea, or other skin conditions linked to LL-37 overexpression. People with autoimmune conditions. Anyone not comfortable with zero human trial data.

Which labs to monitor

• Vitamin D (25-OH) — optimize to 60–80 ng/mL to naturally support LL-37 production
• hsCRP — track inflammation levels
• CBC with differential — monitor white blood cell counts

Related